D
Dominique Amans
Researcher at GlaxoSmithKline
Publications - 10
Citations - 111
Dominique Amans is an academic researcher from GlaxoSmithKline. The author has contributed to research in topics: Bromodomain. The author has an hindex of 4, co-authored 10 publications receiving 94 citations. Previous affiliations of Dominique Amans include University of Hertfordshire.
Papers
More filters
ComponentDOI
Discovery of a Bromodomain and Extraterminal Inhibitor with a Low Predicted Human Dose through Synergistic Use of Encoded Library Technology and Fragment Screening.
Christopher Roland Wellaway,Dominique Amans,Paul Bamborough,Heather Barnett,Rino A Bit,Jack A Brown,Neil R Carlson,Chun-wa Chung,Anthony W. J. Cooper,Peter D. Craggs,Robert P Davis,Tony W Dean,John Evans,Laurie Gordon,Isobel L Harada,David Jonathan Hirst,Philip G Humphreys,Katherine L Jones,Antonia J. Lewis,Matthew J Lindon,Dave Lugo,Mahnoor Mahmood,Scott McCleary,Patricia F Medeiros,Darren J. Mitchell,Michael O'Sullivan,Armelle Le Gall,Vipulkumar Kantibhai Patel,Chris Patten,Darren L Poole,Rishi R Shah,Jane E Smith,Kayleigh A J Stafford,Pamela J Thomas,Mythily Vimal,Ian D. Wall,Robert J. Watson,Natalie Wellaway,Gang Yao,Rab K. Prinjha +39 more
TL;DR: The bromodomain and extraterminal (BET) family of bromidomain-containing proteins are important regulators of the epigenome through their ability to recognize N-acetyl lysine post-translation.
Patent
Furopyridines as bromodomain inhibitors
Dominique Amans,Paul Bamborough,Michael David Barker,Rino Antonio Bit,John Alexander Brown,Matthew Campbell,Neil Stuart Garton,Matthew J Lindon,Tracy Jane Shipley,Natalie Hope Theodoulou,Christopher Roland Wellaway,Susan Marie Westaway +11 more
TL;DR: In this article, the present invention relates to novel compounds, pharmaceutical compositions containing such compounds and their use in therapy, and is related to the use of such compounds in medical applications.
Patent
Tetrahydroquinoline derivatives useful as bromodomain inhibitors
TL;DR: Tetrahydroquinoline (I) derivatives, pharmaceutical compositions containing such compounds and their use in therapy are discussed in detail in this article, where the authors propose a method for synthesizing such compounds.
Patent
Thieno[3,2-C]pyridin-4(5H)-ones as BET inhibitors
Dominique Amans,Paul Bamborough,Rino Antonio Bit,John Alexander Brown,Matthew Campbell,Matthew J Lindon,Tracy Jane Shipley,Natalie Hope Theodoulou,Christopher Roland Wellaway,Susan Marie Westaway +9 more
TL;DR: The use of thienopyridone compounds of formula (I) or a salt thereof in the treatment of diseases or conditions for which a bromodomain inhibitor is indicated is discussed in this paper.
Patent
Dérivés 2,3-disubstitués de 1-acyl-4-amino-1,2,3,4-tétrahydroquinoléine et leur utilisation comme inhibiteurs de bromodomaines
Dominique Amans,Stephen John Atkinson,Lee Andrew Harrison,David Jonathan Hirst,Robert P. Law,Matthew J Lindon,Preston Alexander G,Jonathan Thomas Seal,Christopher Roland Wellaway +8 more
TL;DR: The presente invention concerne des nouveaux composes de formule (I), dans laquelle R 1 represente C 1-4 -alkyle; R 2 represente CH 2 CF 3, -CH 2 OCH 3 ou heterocyclyle; R 3 represente H, halogeno, hydroxy ou c 1-6 -alcoxy; V represente phenyle, heteroaromatique ou pyridone, chacun pouvant eventuellement etre substitue